Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a biotech business focused on the licensing and reselling of cutting-edge technologies and formulations, today announced that its Chief Medical Officer, Dr. Azhar Rana, will be transitioning to an advisory role as of February 1, 2023.
The Company has taken the exciting step of transitioning from research and development to commercialization, and is now recruiting experienced personnel to support its three lines of business – human, plant, and husbandry animal health commercialization. This move will enable the Company to move forward with a revenue-driven business plan and create new opportunities for both the Company and its employees.
Dr. Rana has been a driving force behind MVMD’s progress towards commercialization since joining the company as CMO in August 2021. His skillful guidance and strategic insights have been invaluable to the organization’s success and he will continue to provide his expertise as an advisor under an advisory agreement.
Mountain Valley MD is delighted to welcome Dr. Rana in his new advisory role. They look forward to continuing to work together in this next phase, which is focused on key projects and technologies, generating revenues, and ultimately creating long-term shareholder value. Dr. Rana’s contributions to MVMD are very much appreciated, and they are excited to collaborate with him as they progress.
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is revolutionizing the way we do business with the launch of Quicksome™ oral formulation and delivery technologies, Quicksol™ solubility formulation technology, and Agrarius™, a novel agricultural plant signalling technology. We are dedicated to providing our customers with the highest quality products and services, and are proud to be a world-class organization in the implementation, licensing and reselling of these key technologies and formulations.
MVMD is committed to improving the lives of humans and animals through the use of its own and licensed technologies. From pain management to energy and focus, the company is dedicated to developing innovative solutions that promote health and well-being. Additionally, its partnership with Agrarius is helping to reduce fertilizer usage and increase crop yields, making a positive impact on the agriculture industry. By striving for “More Life”, MVMD is working hard to ensure a better future for everyone.
MVMD’s breakthrough Quicksome™ technology is revolutionizing the way active ingredients are delivered into the body. Our proprietary formulations and stabilizing molecules create highly efficient product formats that make it possible to deliver nutraceutical and drug molecules more quickly and with greater precision than ever before. Unlock the power of this innovative new technology and experience the amazing benefits it can offer.
MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.
Agrairus™, MVMD’s licensed agricultural plant signalling technology, has the potential to revolutionize the agricultural industry. It has been designed to naturally increase crop yields, reduce fertilizer usage, and improve plants’ resilience to pests and climate change. With Agrairus™, farmers and agricultural businesses can benefit from increased productivity and profitability.